Live news related to AB SCIENCE stock (FR0010557264): press releases, earnings publications, share price moves, analyst notes and corporate events. This page is auto-updated whenever new financial information is available.
AB Science announced the publication of a new study on medRxiv assessing the benefits of masitinib in patients with amyotrophic lateral sclerosis. The…
AB Science has received a firm offer for clinical trial financing insurance covering up to €25 million in costs in the event of a failure of its phase…
AB Science stands out with a notable increase this Thursday morning, as its shares rise by 3.69% to 1.236 euros after closing at 1.19 euros the previo…
AB Science stock shows strong progress this Tuesday at midday, recording a gain of 4.15% at 1.306 euros. This advance occurs in a context of a signifi…
AB Science announces the identification of a plasma biomarker capable of assessing the activity of masitinib in the treatment of amyotrophic lateral s…
AB Science announces that the U.S. Food and Drug Administration has granted Minor Use in Major Species (MUMS) status to its Masivet® treatment for the…
AB Science announced that it has received a patent acceptance notification from the U.S. Patent Office for a patent covering the use of masitinib in t…
AB Science has announced that the Japanese Patent Office has issued a patent protecting the use of masitinib in the treatment of progressive forms of …
The French biopharmaceutical group AB Science announced on the evening of January 7 a fourth consecutive clinical response observed with the combinati…
AB Science has reported the results of its phase 1 trial combining AB8939 and venetoclax in patients with refractory or relapsed acute myeloid leukemi…
